帕金森氏症药物市场规模、份额、成长分析，按药物类别、给药方法、年龄、地区 - 产业预测，2025-2032

2023年帕金森氏症药物的全球市场规模为46亿美元，从2024年的50.9亿美元成长到2032年的113.9亿美元，预计在预测期间（2025-2032年）将以复合年增长率成长。 10.6%。

全球帕金森氏症药物市场预计将显着成长，因为目前有超过 1000 万人患有这种神经系统疾病，其特征是多巴胺产生减少以及震颤和僵硬等症状。随着这种疾病的盛行率持续上升，对有效症状管理的需求不断增长，市场将受益于对联合治疗、缓释性药物、基因疗法进展和政府资助的兴趣的增加。此外，人口老化、医疗保健系统改善以及持续研发等因素正在推动市场发展。品牌药物的专利到期和强大的新疗法研发管线在预测期内为该行业的公司提供了利润丰厚的机会，进一步增加了市场潜力。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL分析
• 宏观经济指标
• 价值链分析
• 价格分析

帕金森氏症药物市场规模：依药物类别

• 市场概况
• 脱羧酶抑制剂
• 多巴胺促效剂
• COMT抑制剂
• MAO-B抑制剂
• 其他的

帕金森氏症药物市场规模：依给药方式分类

• 市场概况
• 口服
• 注射
• 经皮的

帕金森氏症药物市场规模：依年龄层划分

• 市场概况
• 50岁以下
• 50岁以上

帕金森氏症药物市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• UCB SA（Belgium）
• GlaxoSmithKline plc（UK）
• Merck & Co., Inc.（USA）
• Boehringer Ingelheim（Germany）
• Lundbeck A/S（Denmark）
• Acadia Pharmaceuticals Inc.（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Amneal Pharmaceuticals, Inc.（USA）
• Supernus Pharmaceuticals, Inc.（USA）
• Kyowa Kirin Co., Ltd.（Japan）
• Orion Corporation（Finland）
• Neurocrine Biosciences, Inc.（USA）
• Acorda Therapeutics, Inc.（USA）
• Ipsen SA（France）
• Luye Pharma Group（China）
• NeuroDerm Ltd.（Israel）（acquired by Mitsubishi Tanabe Pharma）
• Revance Therapeutics, Inc.（USA）

结论和建议

Global Parkinson'S Disease Drug Market size was valued at USD 4.6 billion in 2023 and is poised to grow from USD 5.09 billion in 2024 to USD 11.39 billion by 2032, growing at a CAGR of 10.6% during the forecast period (2025-2032).

The global Parkinson's disease drug market is poised for significant growth, driven by over 10 million individuals currently affected by this neurological disorder, characterized by declining dopamine production and symptoms like tremors and stiffness. As the disease's prevalence rises and the need for effective symptom management continues to grow, the market is benefiting from increased interest in combination therapies, extended-release medications, gene therapy advancements, and supportive government funding. Additionally, factors such as an aging population, improved healthcare systems, and ongoing research and development are bolstering market expansion. The expiration of patents for branded drugs and a strong pipeline of new treatments present lucrative opportunities for industry players during the forecast period, further enhancing the market's potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Parkinson'S Disease Drug market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Parkinson'S Disease Drug Market Segmental Analysis

Global Parkinson'S Disease Drug Market is segmented by drug class, administration, age and region. Based on drug class, the market is segmented into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-b inhibitors and others. Based on administration, the market is segmented into oral, injection and transdermal. Based on age, the market is segmented into < 50 years and > 50 years. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Parkinson'S Disease Drug Market

The global Parkinson's Disease drug market is significantly influenced by several key drivers. Foremost among them is the growing aging population alongside the escalating incidence of Parkinson's disease. As the demographic landscape shifts with an increasing number of elderly individuals, the prevalence of neurological disorders, including Parkinson's, is on the rise. This surge in patient numbers directly correlates with a heightened demand for effective treatment options, thus propelling the market's growth. As a result, this dynamic is anticipated to positively impact the expansion of the Parkinson's Disease drug market worldwide throughout the forecast period.

Restraints in the Global Parkinson'S Disease Drug Market

The global market for Parkinson's disease drugs faces significant restraints primarily due to the high costs associated with treatment. As the prevalence of Parkinson's disease continues to rise, the financial burden on patients, families, and healthcare systems is becoming increasingly pronounced. This economic strain often poses a barrier to accessing necessary treatments and medications, thereby inhibiting the overall growth of the market. Consequently, the prohibitive expense of managing Parkinson's disease is anticipated to serve as a critical challenge for market expansion throughout the forecast period, impacting both patient care and the availability of new therapeutic options.

Market Trends of the Global Parkinson'S Disease Drug Market

The Global Parkinson's Disease Drug market is experiencing substantial growth, driven by a notable surge in research and development funding from both government and corporate sectors aimed at advancing treatment options. This trend is propelling pharmaceutical companies to innovate and introduce new therapeutic drugs that address symptom management and disease modification. Increasing awareness and diagnosis of Parkinson's disease, coupled with a rising geriatric population, further catalyze market expansion. As investments in novel drug development grow, the market is poised for sustained growth, reflecting the increasing commitment to improving patient outcomes and enhancing the quality of life for those affected by Parkinson's disease.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Parkinson's Disease Drug Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Decarboxylase Inhibitors
• Dopamine Agonists
• COMT Inhibitors
• MAO-B Inhibitors
• Others

Global Parkinson's Disease Drug Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injection
• Transdermal

Global Parkinson's Disease Drug Market Size by Age & CAGR (2025-2032)

• Market Overview
• < 50 Years
• >50 Years

Global Parkinson's Disease Drug Market Size & CAGR (2025-2032)

• North America (Drug Class, Administration, Age)
  • US
  • Canada
• Europe (Drug Class, Administration, Age)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Administration, Age)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Administration, Age)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Administration, Age)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Supernus Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Corporation (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acorda Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company OvervSiew
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luye Pharma Group (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroDerm Ltd. (Israel) (acquired by Mitsubishi Tanabe Pharma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revance Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations